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Supplementary methods

Patient material
This study included CLL patients assigned to one of eight major stereotyped subsets #1-8 (n=249) that form part of a large European multicenter cohort; this cohort consisted of Czech (n=85), Greek (n=69), Dutch (n=42), Swedish (n=25), French (n=15), British (n=12), and Italian (n=1) cases. The cohort consisted predominantly of patients with unmutated IGHV genes (76%; 188/249). Clinical and biological features of the patient cohort are summarized in Supplementary Table 1 . The biological material used in this study included separated B-lymphocytes or peripheral blood mononuclear cells.
The leukemic cell fraction was assessed by flow cytometry and exceeded 80% in all cases (median 92%).
ATM mutation analysis
The entire coding region (62 exons) and adjacent splicing sites of the ATM gene were investigated using targeted deep-sequencing approaches (n=237 samples) or Sanger sequencing (n=12 samples).
Concerning the deep sequencing, one hundred and fifty-two samples were analyzed using Haloplex 
Relative telomere length analysis
Telomere length (TL) was assessed by real-time quantitative PCR using -globin (HBB) as a singlecopy gene and Human Genomic DNA (Promega, USA) as a reference DNA. Genomic DNA was extracted from CLL cells following standard protocols and diluted to 20 ng/ l with TE buffer. Prior to TL analysis, DNA from the samples to be analyzed and from the reference human DNA were diluted to a final concentration of 1.75 ng/μl in a TE buffer containing 2.5 ng/ l Escherichia coli DNA (SigmaAldrich, USA). The diluted samples were then denatured at 95°C for 5 min and cooled at 4°C. The PCR master mixes for telomeres (TEL) and HBB were slightly different, however final concentration of 10 mM Tris-HCl (pH 8.0), 10 nM Rox (Thermo Scientific, MA, USA), 1× Maxima Sybr Green qPCR MM (Thermo Scientific, MA, USA) and 1% DMSO was the same for both mixes. Final concentrations specific to the telomere mix were 100nM primer Tel1, 900nM primer Tel2, and 2.5 mM DTT, while for the HBB mix final concentrations were 400nM for both the HBG3 and HBG4 primers, and 5 mM DTT. The volume of each reaction was 25 l, containing 5 l of DNA (total amount 8.8 ng). Cycling conditions for the telomere amplification comprised an initial denaturation step at 95 C for 10 min, and 25 cycles at 95 C for 15 s and 54 C for 1 min. The same denaturation step was used for the HBB amplification, but was then followed by 35 cycles at 95 C for 15 s and 56 C for 1 min. All samples were loaded in triplicates and run on the Stratagene Mx3005P instrument (Agilent Technologies, Santa Clara, CA). Primer sequences for telomeric repeats and the single-copy -globin (HBB) gene are available upon request.
Relative telomere length (RTL) was calculated using the 2 -ΔΔCt method which compared the telomere to the single copy gene (T/S) ratio between a sample and the reference DNA. T/S values were determined using the formula 2 -ΔCt where ΔCt indicates the difference between the average Ct value for telomeres and for the HBB gene. The reference DNA was also used to monitor the PCR efficiency that reached 115% for telomere and 110% for HBB amplification. The inter-assay variability was evaluated under the fixed threshold (0.5 for TEL and 0.3 for HBB) and coefficients of variation (CV)
were calculated to be 4% and 2.23% for Ct TEL and HBB, respectively. The intra-assay variability was measured in seven replicates on one plate and deemed to be 2% and 0.6% for TEL and HBB, respectively. Specificity of the assay was confirmed by gel electrophoresis and melting curve analysis.
Statistical evaluation
The chi-square test ( 2 ) was used to assess differences in mutations frequencies, the Mann-Whitney U test to compare telomere lengths amongst the various subgroups and the log-rank test enabled comparisons of survival curves. All analyses were performed using the free statistical software R
42
.
Overall survival (OS) and time-to-first-treatment (TTFT) were measured from the date of diagnosis until last follow-up/death or date of initial treatment, respectively. The significance level was set at p 0.05. 
